Scancell reports Strong Phase 2 Data on iSCIB1+ in Advanced Melanoma by chantal | Jul 24, 2025 | Immunobody, Investor Presentations, iSCIB1+
Clinical & Corporate Update: Active Immunotherapy for a Cancer-Free Future by chantal | Jun 25, 2025 | Investor Presentations
Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025 by admin | Apr 14, 2025 | Investor Presentations
